Therapie am Phänotyp ausrichten

Die vielen Gesichter der Rosazea

This is a preview of subscription content, log in to check access.

Literatur

  1. 1.

    Buddenkotte J, Steinhoff M. Recent advances in understanding and managing rosacea. F1000Res. 2018; 7: F1000 Faculty Rev-1885

  2. 2.

    Tan J et al. Updating the diagnosis, classification and assessment of rosacea: recommendations from the global ROSacea COnsensus (ROSCO) panel. Br J Dermatol. 2017; 176: 431-8

  3. 3.

    Fessler B. Symptomorientierte Therapie der Rosazea. ästhetische dermatologie & kosmetologie. 2018; 10: 27

  4. 4.

    Woo YR et al. Rosacea: Molecular Mechanisms and Management of a Chronic Cutaneous Inflammatory Condition. Int J Mol Sci. 2016; 17: 1562

  5. 5.

    Sulk M et al. Distribution and expression of non-neuronal transient receptor potential (TRPV) ion channels in rosacea. J Invest Dermatol. 2012; 132: 1253-62

  6. 6.

    Chang ALS et al. Assessment of the genetic basis of rosacea by genome-wide association study. J Invest Dermatol. 2015; 135: 1548-55

  7. 7.

    Yazici AC et al. GSTM1 and GSTT1 null genotypes as possible heritable factors of rosacea. Photodermatol Photoimmunol Photomed. 2006; 22: 208-10

  8. 8.

    van Steensel MA et al. Granulomatous rosacea and Crohn's disease in a patient homozygous for the Crohn-associated NOD2/CARD15 polymorphism R702W. Exp Dermatol. 2008; 17: 1057-8

  9. 9.

    Karpouzis A et al. Assessment of Tachykinin Receptor 3' Gene Polymorphism rs3733631 in Rosacea. Int Sch Res Notices. 2015; 2015: 469402

  10. 10.

    Pietschke K, Schaller M. Long-term management of distinct facial flushing and persistent erythema of rosacea by treatment with carvedilol. J Dermatolog Treat. 2018; 29: 310-3

  11. 11.

    Schaller M et al. Recommendations for rosacea diagnosis, classification and management: update from the global ROSacea COnsensus 2019 panel. Br J Dermatol. 2020; 182: 1269-76

  12. 12.

    Schaller M et al. Rosacea treatment update: recommendations from the global ROSacea COnsensus (ROSCO) panel. Br J Dermatol. 2017; 176: 465-71

  13. 13.

    Schaller M, Pietschke K. Successful therapy of ocular rosacea with topical ivermectin. Br J Dermatol. 2018; 179: 520-1

  14. 14.

    van Zuuren EJ et al. Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments. Br J Dermatol. 2019; 181: 65-79

  15. 15.

    Tanghetti EA et al. Oxymetazoline and Energy-Based Therapy in Patients with Rosacea: Evaluation of the Safety and Tolerability in an Open-Label, Interventional Study. Lasers Surg Med. 2020; https://doi.org/10.1002/lsm.23253

  16. 16.

    Osman M et al. Pulsed dye laser alone versus its combination with topical ivermectin 1 % in treatment of Rosacea: a randomized comparative study. J Dermatolog Treat. 2020; https://doi.org/10.1080/09546634.2020.1737636

  17. 17.

    Al Mokadem SM et al. Efficacy of Topical Timolol 0.5 % in the Treatment of Acne and Rosacea: A Multicentric Study. J Clin Aesthet Dermatol. 2020; 13: 22-7

  18. 18.

    Park KY et al. Botulinum toxin for the treatment of refractory erythema and flushing of rosacea. Dermatology. 2015; 230: 299-301

  19. 19.

    Kim MJ et al. Assessment of Skin Physiology Change and Safety After Intradermal Injections With Botulinum Toxin: A Randomized, Double-Blind, Placebo-Controlled, Split-Face Pilot Study in Rosacea Patients With Facial Erythema. Dermatol Surg. 2019; 45: 1155-62

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Dr. rer. nat. Miriam Sonnet.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sonnet, M. Die vielen Gesichter der Rosazea. ästhet dermatol kosmetol 12, 8–11 (2020). https://doi.org/10.1007/s12634-020-1068-6

Download citation